Details

Autor(en) / Beteiligte

• Haller, Hermann
• Ito, Sadayoshi
• Izzo, Joseph L
• Januszewicz, Andrzej
• Katayama, Shigehiro
• Menne, Jan
• Mimran, Albert
• Rabelink, Ton J
• Ritz, Eberhard
• Ruilope, Luis M
• Rump, Lars C
• Viberti, Giancarlo

Titel

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

Ist Teil von

• The New England journal of medicine, 2011-03, Vol.364 (10), p.907-917

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2011

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• This study investigated whether an angiotensin-receptor blocker (olmesartan) would delay microalbuminuria in patients with type 2 diabetes and normoalbuminuria. Olmesartan was associated with a delayed onset of microalbuminuria, even though blood pressure control in both groups was excellent. Diabetic nephropathy is an increasingly common cause of end-stage renal disease, 1 and the development and rate of renal deterioration are most closely related to the patient's blood pressure. Guideline committees worldwide concur that the blood pressure in patients with diabetes and chronic kidney disease should be kept at 130/80 mm Hg or less. 2 Microalbuminuria is predictive of diabetic nephropathy and premature cardiovascular disease 3 – 5 ; therefore, European and American guidelines recommend that patients with diabetes be tested for microalbuminuria. 6 , 7 Overactivity of the renin–angiotensin system has been implicated in the deterioration of renal function in patients with diabetic nephropathy and . . .